Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Director/PDMR Shareholding

21st Dec 2015 18:22

RNS Number : 8050J
GW Pharmaceuticals PLC
21 December 2015
 



GW Pharmaceuticals PLC Director/PDMR Shareholding

21 December 2015

 

GW Pharmaceuticals PLC ("GW Pharmaceuticals" or the "Company")

NOTIFICATION OF INTERESTS OF DIRECTORS AND CONNECTED PERSONS

 

Cambridge, UK, 21 December 2015: GW Pharmaceuticals (AIM: GWP, NASDAQ:GWPH) hereby provides notification that the Company has been notified of the following series of transactions in the shares of GW Pharmaceuticals plc.

 

On 18 December 2015 the Company was notified that on 17 December 2015 Mr Cabot Brown, a non-executive Director of the Company, purchased 600 American Depository Shares, or ADS (equivalent to 7,200 ordinary 0.1 pence shares) of GW Pharmaceuticals plc, at a price of $68.864 per ADS (equivalent to 384 pence per share).

 

Following this notification Mr Brown's interest in the shares of GW Pharmaceuticals plc is 7,200 ordinary 0.1 pence shares (equivalent to 600 ADSs), representing less than 0.1% of the Company's current issued share capital.

 

On 18 December 2015 Mr. Chris Tovey, a Director and Chief Operating Officer of the Company, exercised options to acquire 24,000 ordinary 0.1 pence shares (equivalent to 2,000 ADSs) of GW Pharmaceuticals plc. These options had an exercise price of 0.1 pence per share. The Company has been notified that on 18 December 2015 these shares, representing less than 0.1% of shares in issue, were converted to 2,000 ADSs and immediately sold at an average price of $67.6275 per ADS (equivalent to 378 pence per share).

 

Following these transactions, Mr. Tovey's beneficial interested in the Company's ordinary 0.1 pence shares is 2,500 shares, representing less than 0.1% of the Company's current issued share capital.

 

On 18 December 2015 Dr. Geoffrey Guy, a Director and Chairman of the Company, exercised options to acquire 1,369,848 ordinary 0.1 pence shares (equivalent to 114,154 ADSs) of GW Pharmaceuticals plc. These options had a weighted average exercise price of 41 pence per ordinary 0.1 pence share. The Company has been notified that (1) on 18 December 2015, 1,065,936 of these shares were converted to 88,828 ADSs and immediately sold at an average price of $67.50 per ADS (equivalent to 377 pence per share) and (2) earlier today a further 10,309 ADSs (equivalent to 123,708 ordinary 0.1 pence shares) were sold at an average price of $67.32 per ADS (equivalent to 376 pence per share). Exercise of these options results in an immediate UK income tax liability for Dr. Guy necessitating the immediate sale of a significant number of the resulting shares. In addition, we have been notified that earlier today 6,000 ordinary 0.1 pence shares held by Dr Guy's personal pension scheme were sold at an average price of 366 pence per share.

 

Following these transactions, Dr. Guy's notifiable interest in the ordinary 0.1 pence shares of the Company has increased by 174,204 shares to 14,297,852 shares, representing 5.4% of the Company's current issued share capital.

 

The total number of shares outstanding in the Company is 262,574,021 ordinary 0.1 pence shares.

 

For further information, please contact:

 

GW Pharmaceuticals plc

Adam George, Company Secretary

+44 (0)1980 557 000

Peel Hunt LLP (UK NOMAD)

James Steel

+44 20 7418 8900

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSLLFFTFLLLFIE

Related Shares:

GWP.L
FTSE 100 Latest
Value8,275.66
Change0.00